Retinal Vein Occlusion: Types, Risk Factors, Symptoms, and Treatment

Retinal vein occlusion (RVO) is the second most common retinal vascular disorder after diabetic retinopathy. Obstruction of a retinal vein causes hemorrhage, macular edema, and ischemia. Prompt diagnosis and treatment are critical for visual preservation.

Classification

  • Central Retinal Vein Occlusion (CRVO): Obstruction at the optic nerve level; entire retina affected. Subtypes: non-ischemic (perfused) vs. ischemic (non-perfused, >10 disc areas capillary non-perfusion).
  • Branch Retinal Vein Occlusion (BRVO): Obstruction at arteriovenous crossing; sectoral retinal involvement. Better visual prognosis than CRVO.
  • Hemi-Retinal Vein Occlusion: Obstruction of superior or inferior trunk—intermediate presentation.

Risk Factors

  • Systemic: Hypertension (most common), diabetes mellitus, hyperlipidemia, cardiovascular disease, hypercoagulable states, elevated homocysteine.
  • Ocular: Glaucoma (elevated IOP compresses vein), optic disc drusen, high hyperopia (crowded disc).
  • Lifestyle: Smoking, obesity, sedentary behavior.

Clinical Presentation

  • CRVO: Sudden, painless vision loss (central if macular edema). Fundus: diffuse retinal hemorrhages in all quadrants, venous dilation/tortuosity, cotton-wool spots, disc edema.
  • BRVO: Sectoral hemorrhages along venous distribution. Macular edema common if macula involved. Vision loss correlates with macular edema and ischemia extent.

Diagnostic Workup

  • OCT: Quantifies macular edema, detects subretinal fluid, vitreoretinal interface.
  • Fluorescein Angiography (FA): Assesses capillary non-perfusion, neovascularization, leakage, transit time.
  • Systemic: Blood pressure, HbA1c, lipid panel, CBC, coagulation studies (if young/unprovoked).

Treatment

Macular Edema (Primary Indication)

  • Anti-VEGF agents (first-line): Aflibercept (Eylea), ranibizumab (Lucentis), bevacizumab (Avastin off-label). Monthly loading (3–6 doses), then treat-and-extend or PRN.
  • Dexamethasone intravitreal implant (Ozurdex): Alternative, especially if anti-VEGF inadequate; monitor IOP/cataract.
  • Laser photocoagulation (grid): Historical role; now second-line for BRVO with edema.

Neovascular Complications

  • Panretinal photocoagulation (PRP): For retinal/iris neovascularization (prevents neovascular glaucoma).
  • Anti-VEGF as temporizing bridge to PRP.

Systemic Management

  • Control hypertension, diabetes, lipids; smoking cessation.
  • Antiplatelet/anticoagulation per primary care/cardiology—not standard for RVO alone.

Prognosis

  • BRVO: Good visual potential with treatment; final acuity often 20/40 or better if macular edema resolves.
  • CRVO: Non-ischemic: better prognosis, may convert to ischemic (10–30%). Ischemic: poor visual recovery, high risk of neovascular glaucoma.

Follow-Up

Regular monitoring (4–8 week intervals initially) for macular edema recurrence, neovascularization, and fellow eye risk (5–10% 5-year risk). Lifelong vascular risk factor control essential.

Eye & Vision Disorders - Related Articles